http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3432882-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3386f5906dc1bdc9c934203594712c66
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
filingDate 2017-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b98244336606864292e231ffc9c44f23
publicationDate 2019-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-3432882-A1
titleOfInvention Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
abstract Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing α-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for α-galactosidase A, wherein the patient has a splice site mutation in intron 4 of the nucleic acid sequence encoding α-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.
priorityDate 2016-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228049094
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394438
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393946
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393712
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7456
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6207
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107428
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393724
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393858
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393714
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394558
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID453
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24749
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45051774
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID643460
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7175
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226543156
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66616222
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5977
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID338
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393830
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11177
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54676860
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226411806
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396434
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID439357
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408336
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6475030
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3423265
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226408335
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226396167
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3037556
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393895

Total number of triples: 55.